---
title: "Humacyte says FDA accepts IND for first-in-human CTEV CABG study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293928671.md"
description: "Humacyte announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human study of its coronary tissue-engineered vessel used in Coronary Artery Bypass Grafting (CABG). The Phase 2a trial is scheduled to begin this quarter, involving 10 adult patients. The study will assess primary patency at two months with follow-ups extending up to three years."
datetime: "2026-07-27T12:03:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293928671.md)
  - [en](https://longbridge.com/en/news/293928671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293928671.md)
---

# Humacyte says FDA accepts IND for first-in-human CTEV CABG study

-   Humacyte secured FDA acceptance of its IND for a first-in-human study of its coronary tissue engineered vessel in CABG. \* Phase 2a trial set to start this quarter in 10 adult patients; primary patency check at two months, follow-up up to three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788296) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte (HUMA) Q2 2026 Earnings Call: Dialysis sBLA Targeted for November](https://longbridge.com/en/news/295902187.md)
- [Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?](https://longbridge.com/en/news/295760868.md)
- [Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints](https://longbridge.com/en/news/295900197.md)
- [Humacyte Q2 net loss widens on inventory, production costs](https://longbridge.com/en/news/295655400.md)
- [Tyga is Hollywood’s latest AI optimist](https://longbridge.com/en/news/296029242.md)